In the first quarter of 2026, Bio Essence Corp reversed prior losses with a significant net income swing fueled by higher OEM supplement sales and tighter expense control. The April acquisition of MediFlow AI software represents a strategic move to diversify offerings beyond traditional herbal supplements. Despite improved earnings, the company grapples with a substantial working capital deficit and ongoing litigation related to lease and contract breaches. Its operational shift from owning manufacturing subsidiaries to an outsourced OEM model enhances flexibility but deepens dependencies on concentrated vendors and customers in a competitive low-moat industry.